Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim recently presented promising preclinical data from its pan-KRAS program including the novel, oral…
Browsing: Boehringer Ingelheim
Boehringer Ingelheim recently presented promising preclinical data from its pan-KRAS program including the novel, oral…